Unity Biotechnology Stock Today
| UBX Stock | USD 1.19 0.05 4.39% |
Performance0 of 100
| Odds Of DistressOver 81
|
Unity Biotechnology is trading at 1.19 as of the 26th of November 2024; that is 4.39 percent increase since the beginning of the trading day. The stock's open price was 1.14. Unity Biotechnology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Unity Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of May 2018 | Category Healthcare | Classification Health Care |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. The company has 16.85 M outstanding shares of which 303.04 K shares are at this time shorted by investors with about 7.7 days to cover. More on Unity Biotechnology
Moving together with Unity Stock
| 0.76 | ME | 23Andme Holding | PairCorr |
| 0.83 | VALN | Valneva SE ADR | PairCorr |
| 0.69 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Unity Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Unity Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsUnity Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Unity Biotechnology's financial leverage. It provides some insight into what part of Unity Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unity Biotechnology (UBX) is traded on NASDAQ Exchange in USA. It is located in 285 East Grand Avenue, South San Francisco, CA, United States, 94080 and employs 19 people. Unity Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 20.05 M. Unity Biotechnology runs under Biotechnology sector within Health Care industry. The entity has 16.85 M outstanding shares of which 303.04 K shares are at this time shorted by investors with about 7.7 days to cover.
Unity Biotechnology has about 64.51 M in cash with (37.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Unity Biotechnology Probability Of Bankruptcy
Ownership AllocationUnity Biotechnology shows a total of 16.85 Million outstanding shares. About 78.16 % of Unity Biotechnology outstanding shares are held by general public with 1.3 (%) owned by insiders and only 20.54 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Unity Ownership Details
Unity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Founders Fund V Management, Llc | 2024-06-30 | 49.2 K | |
| Wells Fargo & Co | 2024-06-30 | 43.4 K | |
| Cercano Management Llc | 2024-09-30 | 41.2 K | |
| State Street Corp | 2024-06-30 | 37.8 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 25 K | |
| Commonwealth Equity Services Inc | 2024-06-30 | 24.6 K | |
| Northern Trust Corp | 2024-09-30 | 22.5 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 17.8 K | |
| Endowment Wealth Management, Inc. | 2024-09-30 | 13.5 K | |
| Arch Venture Corp | 2024-09-30 | 1 M | |
| Alyeska Investment Group, L.p. | 2024-09-30 | 920 K |
Unity Biotechnology Historical Income Statement
Unity Stock Against Markets
Unity Biotechnology Corporate Management
| Dr AB | CoFounder Director | Profile | |
| Nathan Guz | Vice Operations | Profile | |
| Judith Campisi | Founder | Profile | |
| Daohong MD | Founder | Profile | |
| Anirvan Ghosh | CEO Director | Profile | |
| Jamie MD | Chief Officer | Profile |
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.